HALO Halozyme Therapeutics PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: HALO
- PE Ratio
As of May 21, 2025, the HALO stock has a P/E ratio of 14.01. The calculation is based on the latest EPS of $3.85 and the stock price of $53.93 per share. A decrease of 19% has been observed in the PE ratio compared to its average of 17.2 of the past four quarters.
HALO PE ratio history
The mean historical PE ratio of Halozyme Therapeutics over the last eight years is 30.81. The current 14.01 price-to-earnings ratio is 55% less than the historical average. Analyzing the last eight years, HALO's PE ratio reached its highest point in the Sep 2020 quarter at 146, with a price of $26.28 and an EPS of $0.18. The Mar 2022 quarter saw the lowest point at 12.95, with a price of $39.88 and an EPS of $3.08.
Halozyme Therapeutics PE ratio by year
Maximum annual increase: 173.47% in 2022
Maximum annual decrease: -68.73% in 2021
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | 13.66 | -21.27% | $47.81 | $3.5 |
| 2023 | 17.35 | -54.88% | $36.96 | $2.13 |
| 2022 | 38.45 | 173.47% | $56.9 | $1.48 |
| 2021 | 14.06 | -68.73% | $40.21 | $2.86 |
| 2020 | 44.96 | N/A | $42.71 | $0.95 |
| 2019 | N/A | N/A | $17.73 | -$0.5 |
| 2018 | N/A | N/A | $14.63 | -$0.56 |
| 2017 | 44.04 | N/A | $20.26 | $0.46 |
| 2016 | N/A | N/A | $9.88 | -$0.81 |
| 2015 | N/A | N/A | $17.33 | -$0.25 |
| 2014 | N/A | N/A | $9.65 | -$0.56 |
| 2013 | N/A | N/A | $14.99 | -$0.74 |
| 2012 | N/A | N/A | $6.71 | -$0.48 |
| 2011 | N/A | N/A | $9.51 | -$0.19 |
| 2010 | N/A | N/A | $7.92 | -$0.56 |
Halozyme Therapeutics PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2025 | 16.57 | 21.3% | $63.81 | $3.85 |
| Dec 2024 | 13.66 | -26.72% | $47.81 | $3.5 |
| Sep 2024 | 18.64 | -7.08% | $57.24 | $3.07 |
| Jun 2024 | 20.06 | 20.84% | $52.36 | $2.61 |
| Mar 2024 | 16.6 | -4.32% | $40.68 | $2.45 |
| Dec 2023 | 17.35 | -13.25% | $36.96 | $2.13 |
| Sep 2023 | 20 | -3.52% | $38.2 | $1.91 |
| Jun 2023 | 20.73 | -27.8% | $36.07 | $1.74 |
| Mar 2023 | 28.71 | -25.33% | $38.19 | $1.33 |
| Dec 2022 | 38.45 | 47.83% | $56.9 | $1.48 |
| Sep 2022 | 26.01 | 53.72% | $39.54 | $1.52 |
| Jun 2022 | 16.92 | 30.66% | $44 | $2.6 |
| Mar 2022 | 12.95 | -7.89% | $39.88 | $3.08 |
| Dec 2021 | 14.06 | 0.57% | $40.21 | $2.86 |
| Sep 2021 | 13.98 | -49.2% | $40.68 | $2.91 |
HALO Price vs fair value
HALO average PE ratio chart
The current PE ratio of HALO is under its 3, 5 and 10-year averages.
HALO PE vs peers
HALO's PE ratio is below its peer stocks LLY and JNJ. Halozyme Therapeutics's current PE ratio of 14.01 is less than the average of its peers, which is 33.49.
| Stock name | PE ratio | Market cap |
|---|---|---|
| HALO Halozyme Therapeutics Inc | 14.01 | $6.65B |
| PFE Pfizer Inc | 16.58 | $130.99B |
| JNJ Johnson & Johnson | 16.91 | $368.56B |
| MNKD Mannkind Corp | 41.7 | $1.27B |
| LLY ELI LILLY & Co | 58.75 | $687.06B |
| BAX Baxter International Inc | N/A | $15.62B |
Frequently asked questions
What is Halozyme Therapeutics's PE ratio?
As of May 21, 2025, HALO stock has a price to earnings ratio of 14.01.
What is the 3-year average PE ratio for Halozyme Therapeutics (HALO)?
Over the last 3 years, the average PE ratio for HALO stock is 21.14.
What is the 5-year average PE ratio for Halozyme Therapeutics (HALO)?
Over the last 5 years, the average PE ratio for HALO stock is 28.84.
What is the highest PE ratio for HALO?
Over the last eight years, the quarterly PE ratio reached its highest level at 146 in the Sep 2020 quarter.
How does the current PE ratio for HALO compare to its historical average?
HALO's current price to earnings ratio is 55% below its 8-year historical average.
How is HALO's PE ratio calculated (Halozyme Therapeutics PE ratio formula)?
To determine the P/E ratio, divide the latest stock price by the TTM earnings per share (EPS). As of today (May 21, 2025), Halozyme Therapeutics's share price is $53.93. The company's earnings per share for the trailing twelve months (TTM) ending Mar 2025 is $3.85. Therefore, Halozyme Therapeutics's price to earnings ratio for today is 14.01. PE RATIO(14.01) = STOCK PRICE($53.93) / TTM EPS($3.85)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.